News

Instead of a colonoscopy

A new screen tests poop for colorectal cancer–related bacteria
Manisha Roy
By Manisha Roy
Dec. 19, 2020

Let's imagine a patient named John. For the past few months, John has had uncomfortable bowel movements, occasional bloody stool, constipation, and lately, unexplained fatigue. His human fecal immunochemical test (FIT), a preliminary test for colorectal cancer, has signaled the presence of a mass of cells in his large intestine. He's been on a liquid diet for the past day. In the evening, he drinks a Gatorade mixed with laxatives. He'll have another in the morning.

He's preparing for a colonoscopy. John is not alone. Colorectal cancer (CRC) is the third most common cancer, with over 1.8 million new cases and 0.9 million deaths worldwide each year. Though the rate of incidence is lower in middle- and low-income countries, the rate of death is higher than in their high-income counterparts. This can be attributed to fewer resources and not widely available adequate health centers in such nations. 

The availability of a colonoscopy, the traditional method to screen and diagnose individuals with CRC, in such countries is restricted to tertiary hospitals in cities. Many need to travel long distances to get this inconvenient procedure done. As a result, a sizable portion of at-risk people don't show up for the procedure. 

An FIT, which aims to spot hidden red blood cells in feces, is the most accepted non-invasive approach. But it can only detect cancer lesions that are bleeding, which is 35-48% of them. Besides, it is not sensitive enough to detect advanced stages of CRC. Lately, computerized tomography is emerging as an alternative, but it exposes patients to harmful radiation

Intestinal-microbiota-445x395.jpg
PNNL via CCSearch. Licensed under CC BY-NC-SA 2.0
Intestinal microbiota

Intestinal microbiota

PNNL via CCSearch. Licensed under CC BY-NC-SA 2.0

In a new study, researchers at Umeå University in Sweden proposed a convenient diagnosis test for colorectal cancer that uses stool samples. They used measurement of quantity of bacterial species called Parvimonas micra in feces as a microbial biomarker of CRC. 

In the human body, the large intestine is densely populated with microbes, with around ~1014 bacteria living there. Recent studies have shown that variations in the intestinal microbiota are connected with CRC. In last few years, the microbiome's role in formation and progress of intestinal tumor through DNA damage, inflammation, and immunity modulation has come under scrutiny. For instance, researchers have shown that implanting fecal bacteria obtained from CRC patients causes tumor growth in healthy mice.

P. micra is a usually harmless bacterium that resides in our mouth and intestine, though, under some conditions, it may cause severe gum infection and lung abscesses. Earlier studies have shown that it has a role to play in CRC. 

Dietary and lifestyle changes result in creation of an imbalance between the pathogenic bacteria and commensal bacteria. This is sometimes called "dysbiosis" and often results in pathogenic bacterial overgrowth causing various bowel disorders, including CRC.

Three groups of humans were involved in the current experiment. Individuals in one group showed signs of dysbiosis like bowel discomfort and diarrhoea. The second group was of colorectal cancer patients, present in different stages of the disease. The third group was of individuals without dysbiosis complaints and CRC.

The researchers observed an unusually large presence of P. micra in CRC patients compared to non-CRC individuals. Interestingly, neither patients with dysbiosis or non-CRC individuals showed this overgrowth of P. micra. This signifies that in healthy individuals and people with non-CRC dysbiosis, P. micra grows at its usual pace, but that in the presence of a tumor it grows rapidly.

Dysbiosis can be a pre-cancerous stage (but it doesn't have to be). The absence of unusual P. micra growth in dysbiosis shows that the bacteria is not responsible for genesis of tumor lesions. Its high number only in CRC patients indicates that it is an opportunist that begins to grow aggressively, finding a suitable breeding ground offered by the tumor microenvironment. 

Hence, the researchers concluded that it is unlikely that P. micra is responsible for the initiation of cancer. Rather, it is a "passenger" who starts multiplying aggressively in the altered niche around the tumor. 

The "passenger" name comes from a theory called bacterial passenger-driver model, proposed in 2012. This model describes the role of intestinal microbiota in the onset and progress of CRC. It says that cancer of intestinal cells is initiated by bacteria playing the role of a "driver." Examples of such bacteria are members of the family Enterobacteriaceae and the genus Bacteroides spp. They cause DNA damage and promote abnormal multiplication of epithelial cells in the intestine. The process creates an altered niche that paves the way for outgrowth of opportunistic bacteria referred to as "passengers" like Fusobacterium spp., members of the genus Roseburia, and genus Faecalibacterium.

Furthermore, the present test established a specificity of 87% and a sensitivity of 60%. For a medical test, sensitivity and specificity are two important qualities. Sensitivity and specificity are the ability of a test to correctly classify a person as having a disease or not having a disease, respectively.

The researchers found P. micra often growing together with another passenger bacterial species, Fusobacterium nucleatum, in the CRC microbiota. They also found that a combined test that detected both P. micra and F. nucleatum, along with an FIT has superior performance than each one alone. 

This study also found that the number of P. micra is uniform among all stages of cancer — the bacteria blooms in the presence of the tumor and stays high throughout the course of disease. This is significant because it means that this feces-based test can detect late-stage cancer lesions too, where FIT can sometimes fail. Besides, complementing FIT with microbial biomarkers may help to detect non-bleeding tumors, as it doesn't rely on finding red blood cells in stool.

To cap it all, an efficient stool-based test, such as this, could reduce the diagnostic burden of CRC on patients. A convenient collection of fecal samples, which can be later delivered to designated laboratories, will certainly increase participation from patients, especially in countries with limited resources. 

P. micra, in combination with other bacteria biomarkers and FIT, is a suitable candidate for designing a non-invasive screening test for CRC. Moreover, there is a need to create a screening panel consisting of multiple such microbial markers from gut microbiota. This could enhance the overall performance of the panel and may minimize one's need to go through colonoscopy.

This article was originally published by Massive Science. Read the original here.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Manisha Roy
Manisha Roy

Manisha Roy is a biotechnologist at the Kidwai Cancer Institute, Bangalore, India.

Related articles

From the journals: JBC
Emily Ulrich
UTSW researchers discover how food-poisoning bacteria infect the intestines
University of Texas Southwestern Medical Center
From the journals: October 2019
Gelareh (Abulwerdi) Vinueza, Jonathan Griffin & Elizabeth Stivison

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Gene-mutation pathway discovery paves way for targeted blood cancers therapies
News

Gene-mutation pathway discovery paves way for targeted blood cancers therapies

Nov. 3, 2024

A new study by researchers at the universities of Texas and Chicago explains the enzymatic activity that’s needed for tumor suppression in leukemias and other cancers.

Candy binges can overload your gut microbiome
News

Candy binges can overload your gut microbiome

Nov. 2, 2024

While most Halloween candies contain lots of sugar, some are better for your gut microbiome than others.

Water rescues the enzyme
Essay

Water rescues the enzyme

Oct. 31, 2024

“Sometimes you must bend the rules to get what you want.” In the case of using water in the purification of calpain-2, it was worth the risk.

Virtual issue celebrates water in ASBMB journals
Journal News

Virtual issue celebrates water in ASBMB journals

Oct. 30, 2024

Read a dozen gold open-access articles covering exciting research about the society’s 2024 Molecule of the year.

There are worse things in the water than E. coli
News

There are worse things in the water than E. coli

Oct. 29, 2024

E. coli levels determined whether Olympic swimmers could dive into the Seine this past summer. But are these bacteria the best proxy for water contamination?

Biobots arise from the cells of dead organisms
News

Biobots arise from the cells of dead organisms

Oct. 27, 2024

Given the right conditions, certain types of cells are able to self-assemble into new lifeforms after the organism they were once part of has died.